General American Investors Co. Inc. Sells 224,618 Shares of ARS Pharmaceuticals, Inc. $SPRY

Posted by Brenda Bartman on Nov 7th, 2026

General American Investors Co. Inc. cut its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 19.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 908,428 shares of the company’s stock after selling 224,618 shares during the quarter. General American Investors Co. Inc. owned 0.91% of ARS Pharmaceuticals worth $3,915,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SPRY. Rubric Capital Management LP boosted its holdings in ARS Pharmaceuticals by 29.0% during the first quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $64,240,000 after purchasing an additional 1,800,000 shares during the last quarter. BlackRock Inc. acquired a new position in ARS Pharmaceuticals during the second quarter valued at approximately $42,544,000. ADAR1 Capital Management LLC grew its stake in ARS Pharmaceuticals by 268.4% in the first quarter. ADAR1 Capital Management LLC now owns 1,361,536 shares of the company’s stock valued at $10,933,000 after purchasing an additional 991,967 shares in the last quarter. Tejara Capital Ltd bought a new position in ARS Pharmaceuticals in the second quarter valued at approximately $4,862,000. Finally, Bank of America Corp DE bought a new position in ARS Pharmaceuticals in the second quarter valued at approximately $3,711,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals News Roundup

Here are the key news stories impacting ARS Pharmaceuticals this week:

Positive Sentiment: ARS said neffy’s U.S. market share has surpassed 5% and is targeting cash-flow breakeven by year-end 2027, offering investors signs of product adoption and a longer-term financial milestone. Article: ARS targets cash-flow breakeven as neffy share surpasses 5%
Neutral Sentiment: Raymond James cut its rating from Strong Buy to Outperform but maintained a $17 price target. The downgrade may temper sentiment, though the firm’s revised rating remains positive. Article: Raymond James rating and price target
Negative Sentiment: Third-quarter results fell short of expectations: ARS reported a $0.36-per-share loss versus an approximately $0.30 consensus loss, while revenue of $37.71 million missed the $41.99 million estimate. The shortfall could weigh on near-term sentiment. Article: ARS reports Q3 loss and misses revenue estimates

ARS Pharmaceuticals Stock Performance

SPRY stock traded up $0.14 during midday trading on Friday, reaching $2.79. 5,672,082 shares of the company were exchanged, compared to its average volume of 1,668,914. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. The business has a 50-day moving average price of $4.29 and a two-hundred day moving average price of $7.22. ARS Pharmaceuticals, Inc. has a one year low of $2.44 and a one year high of $13.15. The firm has a market capitalization of $277.47 million, a price-to-earnings ratio of -1.38 and a beta of 0.98.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). The company had revenue of $37.71 million during the quarter, compared to the consensus estimate of $41.99 million. ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. Equities research analysts forecast that ARS Pharmaceuticals, Inc. will post -1.91 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on SPRY. Leerink Partners set a $15.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, September 8th. Weiss Ratings cut shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Finally, Raymond James Financial downgraded shares of ARS Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Friday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

Check Out Our Latest Research Report on ARS Pharmaceuticals

About ARS Pharmaceuticals

(Free Report)

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.